Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)Retained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming (PHAR) Long-Term Deferred Tax (2019 - 2025)

Historic Long-Term Deferred Tax for Pharming (PHAR) over the last 7 years, with Q3 2025 value amounting to $27.5 million.

  • Pharming's Long-Term Deferred Tax fell 2521.5% to $27.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.5 million, marking a year-over-year decrease of 2521.5%. This contributed to the annual value of $30.5 million for FY2024, which is 263.1% up from last year.
  • Per Pharming's latest filing, its Long-Term Deferred Tax stood at $27.5 million for Q3 2025, which was down 2521.5% from $31.2 million recorded in Q2 2025.
  • Pharming's Long-Term Deferred Tax's 5-year high stood at $39.0 million during Q2 2024, with a 5-year trough of $21187.0 in Q3 2022.
  • Its 5-year average for Long-Term Deferred Tax is $23.1 million, with a median of $26.6 million in 2023.
  • As far as peak fluctuations go, Pharming's Long-Term Deferred Tax plummeted by 9990.13% in 2022, and later surged by 12548644.45% in 2023.
  • Pharming's Long-Term Deferred Tax (Quarter) stood at $21414.0 in 2021, then surged by 107180.31% to $23.0 million in 2022, then rose by 29.55% to $29.8 million in 2023, then grew by 2.63% to $30.5 million in 2024, then dropped by 10.02% to $27.5 million in 2025.
  • Its Long-Term Deferred Tax stands at $27.5 million for Q3 2025, versus $31.2 million for Q2 2025 and $18.4 million for Q1 2025.